Embryonic stem cell therapy-heart failure - Lineage Cell Therapeuitcs
Alternative Names: CM-1; GRNCM 1Latest Information Update: 02 Oct 2021
At a glance
- Originator Geron Corporation
- Developer Asterias Biotherapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics
- 11 Mar 2019 Asterias Biotherapeutics has been acquired and merged into BioTime
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA (Intracoronary, Implant)